Lerdelimumab Biosimilar - Research Grade

Human

TGFB2

5mg/ml

IgG4 - lambda2

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P61812

Blue ice

Transforming growth factor beta-2 (TGFB2) regulates wound healing and scarring, a target studied across fibrosis and ocular-tissue research. This recombinant anti-human TGFB2 monoclonal is an unconjugated, non-therapeutic analog of lerdelimumab, supplied for research use only (RUO). It is manufactured to in vivo standards, carries low endotoxin, and is produced in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. Use it in functional assays, cytokine-neutralisation and fibrosis-signalling studies, reproducible controls, and in vivo models of tissue remodelling, with the lot-to-lot consistency needed for sustained, heavy-usage research.

Detects human TGFB2

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks